Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameRecbio-B
Stock Code02179
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是一家疫苗公司,擁有高價值亞單位疫苗組合,並由自主研發的技術所驅動。我們主要專注於HPV候選疫苗的研發。我們的疫苗組合有12款疫苗,包括我們的核心產品REC603,一款重組HPV九價疫苗,目前處於III期臨床試驗階段。
Listing Date2022-03-31
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中国 江蘇省 泰州市 中國醫藥城 疫苗工程中心A217室
Business Address (Hong Kong)香港 灣仔 皇后大道東248號 大新金融中心40樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websiterecbio.cn
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 24.80 / shares
Offer Price RangeFinal offer price only, no range
Lot Size500 shares
Entry ThresholdHK$ 12,400
Par ValueRMB 1.0 / shares
Offer Period2022-03-21 to 2022-03-24
Global Offering Shares30,854,500 shares
HK Public Offer Shares (Initial)3,085,500 shares (10.0%)
Public Offer Lots (Initial)6,171lots (Pool A3,085lots,Pool B3,086lots)
International Placing Shares (Initial)27,769,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO479,104,500 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share54.2%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 765,191,600

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 500 HK$ 12,400
2 lots 1,000 HK$ 24,800
3 lots 1,500 HK$ 37,200
4 lots 2,000 HK$ 49,600
5 lots 2,500 HK$ 62,000
6 lots 3,000 HK$ 74,400
7 lots 3,500 HK$ 86,800
8 lots 4,000 HK$ 99,200
9 lots 4,500 HK$ 111,600
10 lots 5,000 HK$ 124,000
12 lots 6,000 HK$ 148,800
14 lots 7,000 HK$ 173,600
16 lots 8,000 HK$ 198,400
18 lots 9,000 HK$ 223,200
20 lots 10,000 HK$ 248,000
30 lots 15,000 HK$ 372,000
40 lots 20,000 HK$ 496,000
50 lots 25,000 HK$ 620,000
60 lots 30,000 HK$ 744,000
70 lots 35,000 HK$ 868,000
80 lots 40,000 HK$ 992,000
90 lots 45,000 HK$ 1,116,000
100 lots 50,000 HK$ 1,240,000
120 lots 60,000 HK$ 1,488,000
140 lots 70,000 HK$ 1,736,000
160 lots 80,000 HK$ 1,984,000
180 lots 90,000 HK$ 2,232,000
200 lots 100,000 HK$ 2,480,000
400 lots 200,000 HK$ 4,960,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
600 lots 300,000 HK$ 7,440,000
800 lots 400,000 HK$ 9,920,000
1,000 lots 500,000 HK$ 12,400,000
1,200 lots 600,000 HK$ 14,880,000
1,400 lots 700,000 HK$ 17,360,000
2,000 lots 1,000,000 HK$ 24,800,000
3,085 lots 1,542,500 HK$ 38,254,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
HK Market Cap HK$ 1.95B
Est. Threshold HK$ 9.39B
Analysis Result HK market cap below threshold, need +380%

Valuation & Financials

Market Cap (at Offer Price)HK$ 11,881,791,600
H-Share Market Cap (at Offer Price)HK$ 2,226,584,176
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不适用(公司处于亏损状态)
Profit/Loss Status亏损人民币179.4百万元
Period-End Cash Balance人民币355.8百万元
Listing Expenses~HK$ 92,791,600
Listing Expenses / Funds Raised~12.13%
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 20202021
Other income and gains, net 9,55127,810
Administrative expenses -18,416-143,045
Net finance costs -37,112-56,308
Profit before tax -179,400-657,566
Income tax expense 00
Profit for the year -179,400-657,566
Profit attributable to owners -179,400-657,561
Balance Sheet
Item 20202021
Cash and cash equivalents 355,8211,182,562
Inventories 7,76223,549
Total current assets 709,3761,294,571
Total current liabilities 57,481139,293
Total equity -1,008,7841,673,296
Interest-bearing borrowings 050,000
Cash Flow Statement
Item 201920202021-09
Net cash from operating activities -138,639-70,336
Net cash from investing activities -345,639-258,587
Net cash from financing activities 490,171680,385
Depreciation of PP&E 1,4526,55610,394
Depreciation of right-of-use assets 2,8746,2075,621
Purchase of PP&E -78,966-138,288-195,773
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 25.25
First Day OpenHK$ 25.0
First Day Change1.81%
First Day Volume3440000.0
First Day Turnover86207200.0
Use of Proceeds
1、約47.3%或317.9百萬港元將分配予繼續優化、開發及商業化我們的HPV疫苗管線; 2、約17.7%或119.3百萬港元將用于我們新冠肺炎疫苗(即ReCOV)的臨床前及臨床研究、注冊; 3、約21.1%或142.0百萬港元將用于其他候選疫苗的臨床前及臨床研究、注冊; 4、約6.7%或44.7百萬港元將用于進一步加強我們的研發能力及提高營運效率;5、約7.2%或48.5百萬港元將用作我們的營運資金及一般企業用途。

Underwriting Syndicate

Joint Sponsors (3)
Morgan Stanley Asia Limited CE AAD291 招银国际融资有限公司 CE AVM940 中信证券(香港)有限公司 CE AAK249
Overall Coordinators (3)
Morgan Stanley Asia Limited CE AAD291 招银国际融资有限公司 CE AVM940 中信里昂证券有限公司 CE AAB893
Joint Bookrunners (8)
Morgan Stanley Asia Limited CE AAD291 招银国际融资有限公司 CE AVM940 中信里昂证券有限公司 CE AAB893 CHINA INDUSTRIAL SECURITIES INTERNATIONAL CAPITAL LIMITED CE BAK956 海通国际证券有限公司 CE AAF806 广发证券(香港)经纪有限公司 CE AOB364 SDIC SECURITIES (HONG KONG) LIMITED CE AUW685 VALUABLE CAPITAL LIMITED CE AUL711
Joint Lead Managers (9)
Morgan Stanley Asia Limited CE AAD291 招银国际融资有限公司 CE AVM940 中信里昂证券有限公司 CE AAB893 CHINA INDUSTRIAL SECURITIES INTERNATIONAL CAPITAL LIMITED CE BAK956 海通国际证券有限公司 CE AAF806 广发证券(香港)经纪有限公司 CE AOB364 SDIC SECURITIES (HONG KONG) LIMITED CE AUW685 VALUABLE CAPITAL LIMITED CE AUL711 Livermore Holdings Limited CE BJN764

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Harvest International Premium Value (Secondary Market) Fund SPC 78,231,600 HKD — 10.22% — 6 months 2022-09-30
2 SCC Growth VI Holdco C (HK) Limited 7,812,000 HKD — 1.02% — 6 months 2022-09-30
3 SCHP Master Fund 15,636,400 HKD — 2.04% — 6 months 2022-09-30
4 扬子江(香港)有限公司 312,938,800 HKD — 40.90% — 6 months 2022-09-30

Directors & Management

PositionChinese nameEnglish Name
Chairman劉勇—
Company Secretary陳青青、劉准羽—
No director data available.

Major Shareholders

Major Shareholders & Holdings劉博士透過泰州元工等受控法團持有約20.18%權益,為最大股東。
About this page

This page shows Recbio-B (02179) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect